Wells Fargo cuts LeMaitre Vascular stock price target on margin miss

LeMaitre Vascular reported third-quarter 2026 sales of $68 million, up 12% organically and modestly above estimates, but EPS of $0.65 missed the $0.69 forecast; gross and operating margins also came in below estimates. Wells Fargo cut its price target to $86 from $94 and maintained Equal Weight, while Citizens lowered its target to $110 from $127 but kept Market Outperform. LeMaitre paid $19.2 million for B. Braun vascular assets, which generated $9.4 million in 2025 sales; the transition is expected to take 18–24 months, with first-year customer attrition projected at 10%–15%.

Analysis

The key issue is earnings conversion, not demand: pricing accounts for more of growth than volume, while gross and operating margins missed expectations. If price-led growth continues without volume acceleration, investors may question its durability—especially as downward estimate revisions raise the bar for evidence of a margin rebound. The B. Braun asset purchase broadens LMAT’s portfolio, but the 18–24 month commercial handoff makes near-term reported revenue a poor read-through to the assets’ eventual contribution. First-year attrition and delayed direct fulfillment create execution risk; profit sharing may cushion the transition but does not eliminate uncertainty about customer retention or realized economics. Near term, estimate revisions and margin commentary are likely to matter more than the small sales beat. Over 1–3 months, watch order conversion and direct-sales ramp; over 6–18 months, successful retention and cross-selling could support growth, while a prolonged handoff could weigh on returns and valuation. B. Braun monetizes the assets, while competing vascular-product suppliers could face incremental competitive pressure if LMAT converts the installed customer base. Contrarian angle: the growth profile may be intact, but the market could be underestimating how long acquisition revenue takes to become visible in LMAT’s reported results. No directional trade is compelling without a clearer margin and transition read-through.

Key Decisions for Investors

• Keep LMAT neutral rather than chase the revenue beat; the earnings miss and estimate revisions make margin recovery the more important confirmation signal.
• Treat the B. Braun assets as a watch item, not a near-term earnings catalyst. Track direct fulfillment, customer attrition, and whether reported sales begin to reflect the acquired business over the stated transition period.
• Reassess positively if subsequent results show operating-margin stabilization alongside continued organic growth and a credible direct-sales ramp; turn more cautious if margins weaken further or management indicates attrition or transition timelines are worse than expected.